Below are showcased publications produced by NOAHE Members. If you are a NOAHE member and would like to have your publication featured on our website and on social media affiliated with the Network, please contact us at firstname.lastname@example.org; Not a NOAHE member? Sign up here!
Please note: The publications listed on this page serve to showcase the work of our individual members only, and do not necessarily represent the views of the Network of Alberta Health Economists (NOAHE), NOAHE Members, and/or NOAHE funders.
The price of whole genome sequencing may be decreasing, but who will be sequenced?
Since whole-genome sequencing (WGS) information can have positive and negative personal utility for individuals, we examined predictors of willingness to pay (WTP) for WGS. Patients & methods: We surveyed two independent populations: adult patients (n = 203) and college seniors (n = 980). Ordinal logistic regression models were used to characterize the relationship between predictors and WTP. Results: Sex, age, education, income, genomic knowledge and knowing someone who had genetic testing or having had genetic testing done personally were associated with significantly higher WTP for WGS. After controlling for income and education, males were willing to pay more for WGS than females. Conclusion: Differences in WTP may impact equity, coverage, affordability and access, and should be anticipated by public dialog about related health policy.
Authors: Deborah Marshall,Karen V MacDonald, Jill Oliver Robinson, Kathryn A Phillips
Publication date: March 2017
Achieving optimal technology use: A proposed model for health technology reassessment
Healthcare providers, managers and policy-makers in many jurisdictions are focused on a common goal: optimizing value and quality of care provided to their citizens within a resource envelope. Health technology reassessment is a structured, evidence-based assessment of the clinical, social, ethical and economic effects of a technology currently used in the healthcare system to inform optimal use of that technology in comparison with its alternatives. There are, however, few practical experiences with health technology reassessment and, as such, a nascent theoretical and methodological base. Health technology reassessment is a key strategy to achieve optimal healthcare resource utilization, and establishing a model for health technology reassessment is a required methodological step.
Authors: Lesley JJ Soril, Gail MacKean, Tom W Noseworthy, Laura E Leggett, and Fiona M Clement
Publication date: April 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA-Prelim Trial
Precision medicine is heralded as offering more effective treatments to smaller targeted patient populations. In breast cancer, adjuvant chemotherapy is standard for patients considered as high-risk after surgery. Molecular tests may identify patients who can safely avoid chemotherapy. The objective of this paper is to use economic analysis before a large-scale clinical trial of molecular testing to confirm the value of the trial and help prioritize between candidate tests as randomized comparators.
Authors: Peter S. Hall PhD, Alison Smith Msc, Claire Hulme PhD, Armando Vargas-Palacios PhD, Andreas Makris MD, Luke Hughes-Davies PhD, Janet A. Dunn PhD, John M.S. Bartlett PhD, David A. Cameron MD, Andrea Marshall PhD, Amy Campbell BA, Iain R. Macpherson PhD, Dan Rea PhD, Adele Francis PhD, Helena Earl PhD, Adrienne Morgan PhD, Robert C. Stein PhD, Christopher McCabe PhD
Publication date:July 2017
Innovative Funding Models: Kidney Care Policy Options for the Future – Summary Report
The current approach to funding kidney care in Alberta is not aligned with the strategic goals for Alberta Kidney Care, and the Alberta Health Services Kidney – Strategic Clinical Network, including increasing the appropriate use of home dialysis, non-dialysis supportive care, and kidney transplantation. Current funding models, which are not well aligned with these priorities, should be re-examined to ensure consistent access to the most effective evidencebased therapies across the province, and to capitalize on new technologies that would support patients and caregivers for greater independence.
Publication date: November 2015
The State of Health Economics in Alberta: A Review of Need, Capacity, and Action
Cost is a critical element in almost all public or private decisions regarding health care and human services. While cost as “opportunity cost” is straightforward on a conceptual level, making the concept operational, quantifying costs and integrating such information into decision analysis is a continuing challenge. An IHE conference, “On the State of the Art in Costing Methods: Workshop” was held January 21-22, 2015.
Publication date: May 2015
On the State of the Art in Costing Methods: Summary Report
The discipline of health economics can provide important information that can form part of the evidence-base for health care decision-making in Alberta. This work, conducted by the Institute for Health Economics (IHE) and the University of Calgary (Health Economics group), was performed to better understand the unmet educational needs and health economics products that could support people in the province, and to determine the current capacity for conducting health economics in Alberta
Publication date: April 2015